Skip to main content
Log in

5-HT2C receptor activation decreases appetite and body weight in obese subjects

  • RAPID COMMUNICATION
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

We studied the effect of 2 weeks administration of the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP), on appetite and body weight in 18 moderately obese subjects in a double-blind, placebo-controlled trial. mCPP caused a small but significant (0.75 kg) reduction in body weight and in subjective ratings of hunger. Plasma prolactin was significantly elevated by the final dose of mCPP. Our data suggest that during 2 weeks treatment in humans, mCPP may continue to activate brain 5-HT2C receptors, and that this effect is associated with decreases in appetite and body weight.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 20 May 1997 /Final version: 10 July 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sargent, P., Sharpley, A., Williams, C. et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133, 309–312 (1997). https://doi.org/10.1007/s002130050407

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002130050407

Navigation